Product details

This is the third of a four-case series (IMD-3-1496 to IMD-3-1499). The (C) part of the series focuses on the actions GlaxoSmithKline (GSK) had to take after being pressured by the non-government organisations (NGO''s). The company had been defeated and it agreed to several licensing agreements and price reductions, but the NGO''s are still not satisfied. The topic was also gaining importance in the Western media and the big question now was whether it was starting to become an issue in more developed countries, where the vast majority of GSKs'' sales and profits were being made.